Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | ATP4A | P20648 | 2/20 | 0.40 |
| ▸ | ATP4B | P51164 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2379523 | 0.81 | POLB (0.54) | GAAMAPTALDH1A1TDP1KDM4E | |
| SCHEMBL2379967 | 0.80 | NPC1 (0.39) | GAAMAPTALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL2380784 | 0.79 | ATP4A (0.53) | MAPTMAPK1HTTATP4AATP4B | |
| SCHEMBL2379645 | 0.78 | ATP4A (0.43) | GAAMAPTALDH1A1TDP1KDM4E | |
| SCHEMBL2380712 | 0.77 | ROCK2 (0.47) | GAAMAPTALDH1A1MAPK1TDP1 | |
| SCHEMBL2380681 | 0.77 | ROCK2 (0.61) | MAPTHPGDATP4AATP4B | |
| SCHEMBL2379949 | 0.76 | ATP4A (0.49) | GAAALDH1A1MAPK1TDP1KDM4E | |
| SCHEMBL2383760 | 0.74 | ATP4A (0.48) | MAPTALDH1A1KDM4EATP4AATP4B | |
| SCHEMBL2381519 | 0.74 | ROCK2 (0.52) | GAAMAPTALDH1A1MAPK1TDP1 | |
| SCHEMBL2445321 | 0.74 | ATP4A (0.43) | GAAMAPTALDH1A1MAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170037016-A1 | GUANIDINE COMPOUNDS AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBVIE DEUTSCHLAND (DE) | 2017-02-09 | — | — | US | disclosed |
| US-9475782-B2 | Guanidine compounds, and use thereof as binding partners for 5-HT5 receptors | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-10-25 | — | — | US | disclosed |
| US-20130324537-A1 | GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBOTT LABORATORIES (US) | 2013-12-05 | — | — | US | disclosed |
| US-8481576-B2 | Guanidine compounds, and use thereof as binding partners for 5-HT5 receptors | ABBOTT GMBH & CO. KG (DE) | 2013-07-09 | — | — | US | disclosed |
| US-8431604-B2 | Guanidine compounds, and use thereof as binding partners for 5-HT5 receptors | ABBOTT GMBH & CO. KG (DE) | 2013-04-30 | — | — | US | disclosed |
| EP-2380885-A1 | Guanidine compounds and use of same as binding partners for 5-HT5 receptors | Abbott GmbH & Co. KG (DE) | 2011-10-26 | — | — | EP | disclosed |
| US-20110237589-A1 | GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2011-09-29 | — | — | US | disclosed |
| EP-2366392-A1 | Guanidine compounds and use of same as binding partners for 5-HT5 receptors | Abbott GmbH & Co. KG (DE) | 2011-09-21 | — | — | EP | disclosed |
| EP-2366697-A1 | Guanidine compounds and use of same as binding partners for 5-HT5 receptors | Abbott GmbH & Co. KG (DE) | 2011-09-21 | — | — | EP | disclosed |
| US-20070299074-A1 | Guanidine Compounds, and Use Thereof as Binding partners for 5-Ht5 Receptors | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130324537-A1 | GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | HTR5A, GRM5, TAAR5 | GAA 1396/4885MAPT 72/4885ALDH1A1 2830/4885 |
| US-20170037016-A1 | GUANIDINE COMPOUNDS AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | HTR5A, GRM5, GRK5 | GAA 1468/4885MAPT 73/4885ALDH1A1 3189/4885 |
| US-20070299074-A1 | Guanidine Compounds, and Use Thereof as Binding partners for 5-Ht5 Receptors | HTR5A, GRM5, TAAR5 | GAA 1396/4885MAPT 72/4885ALDH1A1 2830/4885 |
| US-20110237589-A1 | GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | HTR5A, GRM5, TAAR5 | GAA 1396/4885MAPT 72/4885ALDH1A1 2830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.